)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ion Beam Applications
Ion Beam Applications (IBAB) investor relations material
Ion Beam Applications Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Revenue for H1 2026 grew 6% year-over-year to €324 million, with adjusted EBIT up 66% to €17.6 million and net profit at €9.3 million, reflecting strong profitability improvements.
Gross margin improved to 33.7% from 29.5% year-over-year, driven by favorable equipment mix and operational efficiencies.
Equipment order intake rose 64% year-over-year to €176 million, keeping backlog stable at €1.6 billion, with strong commercial momentum in proton therapy and radiopharma.
Leadership and Board were strengthened with new appointments and expertise to support strategic execution and growth.
Financial highlights
Net sales reached €323.7 million (+6% YoY), with adjusted EBIT at €17.6 million (+€7 million YoY) and net result at €9.3 million.
Gross margin rose to 33.7% (+4.1 p.p. YoY), and EBIT margin increased to 5.4% (vs. 3.5% prior year).
Net debt increased to €81 million, mainly due to working capital movements and ERP migration delays.
Net leverage ratio at 1.14x adjusted EBITDA; group retains ample access to credit lines.
Cash position at €43.6 million at H1 2026, down from €64.7 million at FY2025.
Outlook and guidance
FY2026 adjusted EBIT guidance reiterated at a minimum of €32 million.
Mid-term outlook (2024–2028) targets 5–7% revenue CAGR and ~10% EBIT margin by 2028, with profitability trajectory supported by backlog and commercial momentum.
Working capital and net debt expected to improve markedly in H2 2027 as major Spanish contracts are delivered.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ion Beam Applications
- Stable backlog and innovation drive strong Q1 2026, with EBIT guidance reaffirmed at €32 million.IBAB
Q1 2026 TU - Record revenue, historic backlog, and strong profitability support a robust 2026 outlook.IBABH2 2025
- Order intake up 6% to €195M, FY2025 REBIT guidance confirmed, and €135M refinancing secured.IBABQ3 2025 TU
- Revenue up 40% to EUR 304.9M, REBIT at EUR 10.6M, guidance reaffirmed amid FX and geopolitical risks.IBABH1 2025
- Record backlog and strong order intake drive positive outlook and growth targets.IBABQ3 2024 TU
- Revenue up 21.9%, margin improved, net loss narrowed, and outlook remains strong.IBABH1 2024
- Targets 5%-7% annual growth and 10% EBIT/REBIT margin by 2028, leveraging innovation and global scale.IBABCMD 2025
- Q1 2025 shows robust growth, €1.5B backlog, and reaffirmed profitability guidance.IBABQ1 2025 TU
- Record revenue, profitability, and a €1.5B backlog support strong growth outlook.IBABH2 2024
Next Ion Beam Applications earnings date
Q3 202626 Nov, 2026
Ion Beam Applications
Next Ion Beam Applications earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ion Beam Applications SA is a Belgian company specializing in proton therapy and particle acceleration technologies, primarily for applications in medical diagnostics and cancer treatment. IBA designs and manufactures advanced proton therapy systems used in precision radiation therapy, as well as particle accelerators for applications in industrial sterilization and medical imaging. The company also offers associated software solutions and maintenance services to healthcare providers and research institutions worldwide. Ion Beam Applications SA is headquartered in Louvain-la-Neuve, Belgium, and its shares are listed on Euronext Brussels.